Literature DB >> 2990759

Renal nerve stimulation causes alpha 1-adrenoceptor-mediated sodium retention but not alpha 2-adrenoceptor antagonism of vasopressin.

D D Smyth, S Umemura, W A Pettinger.   

Abstract

Renal alpha 2-adrenoceptor stimulation by epinephrine infusion reverses cyclic adenosine monophosphate-mediated effects of vasopressin on sodium and water excretion. We used this response to determine whether renal nerve stimulation can activate renal alpha 2-adrenoceptors in the non-recirculating isolated perfused rat kidney (Krebs-Henseleit solution; 3.5 g/100 ml Ficoll; 1 g/100 ml albumin; 36 degrees C; propranolol 100 nM). In the presence of alpha 1-adrenoceptor blockade with prazosin (30 nM) alpha 2-adrenoceptor stimulation with epinephrine reversed the cyclic adenosine monophosphate-mediated effects of vasopressin on sodium (P less than 0.05) and water (P less than 0.05) excretion. Subthreshold (for vasoconstriction) renal nerve stimulation (10 V; 1 msec; 0.65 +/- 0.10 Hz) failed to alter the effect of vasopressin. Similarly, higher levels of renal nerve stimulation [plus prazosin (100 nM) or phenoxybenzamine (1.0 mg/kg per hr) to block alpha 1-adrenoceptors] did not activate renal alpha 2-adrenoceptors which are associated with the antagonism of the effects of vasopressin. The same level of subthreshold renal nerve stimulation (0.85 +/- 0.14 Hz) in the absence of vasopressin, and without alpha 1- or alpha 2-adrenoceptor blockade, decreased (P less than 0.05) sodium and water excretion. The reversal of this effect by alpha 1-adrenoceptor blockade (prazosin 30 nM) but not alpha 2-adrenoceptor blockade (yohimbine 300 nM) indicates that this effect of renal nerve stimulation is mediated through alpha 1-adrenoceptors. Thus, subthreshold renal nerve stimulation in the rat kidney induces sodium and water retention through activation of alpha 1-adrenoceptors, as shown by others in the rabbit and dog.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990759     DOI: 10.1161/01.res.57.2.304

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

Review 1.  Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.

Authors:  William A Pettinger
Journal:  J Cardiovasc Pharmacol       Date:  2017-03       Impact factor: 3.105

2.  Effects of brimonidine ingestion on cardiovascular responses and renal function in conscious dogs.

Authors:  S Suwanwipat; C Buranakarl; N Chaiyabutr
Journal:  Vet Res Commun       Date:  2006-12-28       Impact factor: 2.459

3.  An investigation into the alpha-adrenoceptor mediating renal nerve-induced calcium reabsorption by the rat kidney.

Authors:  E J Johns; J Manitius
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

4.  Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure.

Authors:  M Metra; S Nodari; E Boldi; L Dei Cas
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

5.  Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine.

Authors:  D R Allan; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

6.  Renal imidazoline preferring sites and solute excretion in the rat.

Authors:  D R Allan; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  Central and renal I1 imidazoline preferring receptors: two unique sites mediating natriuresis in the rat.

Authors:  S B Penner; D D Smyth
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

8.  Chronic prazosin attenuates the natriuretic response to a modest saline load in anaesthetized rats.

Authors:  S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

Review 9.  α 2-Adrenoceptors: Challenges and Opportunities-Enlightenment from the Kidney.

Authors:  William A Pettinger; Edwin K Jackson
Journal:  Cardiovasc Ther       Date:  2020-04-29       Impact factor: 3.023

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.